ONL Therapeutics

ONL Therapeutics is a private, pre-revenue biotech founded in 2009 and based in Ann Arbor, Michigan. The company is advancing a platform focused on inhibiting the Fas receptor to prevent retinal cell death, with its lead candidate, ONL1204, being evaluated in a Phase 2 study for acute primary angle-closure glaucoma (APACG). ONL's strategy targets high-unmet-need ophthalmic indications where neuroprotection could prevent irreversible vision loss, positioning it in the growing retinal therapeutics market. Its scientific foundation is built on research from the University of North Carolina and the University of Michigan.

Platform focused on inhibiting the Fas receptor signaling pathway to prevent apoptosis (programmed cell death) in retinal cells, enabling neuroprotection and potential regeneration.

ONL operates in the competitive but nascent field of ophthalmic neuroprotection. Direct competitors include companies developing alternative anti-apoptotic agents (e.g., caspase inhibitors) or neurotrophic factors. It also faces indirect competition from companies targeting downstream disease processes in glaucoma (e.g., neuroinflammation) and from the recently approved complement inhibitors for geographic atrophy, which work via a different mechanism.